IART NASDAQ
Integra LifeSciences Holdings Corporation
1W: +4.3%
1M: +40.6%
3M: +23.8%
YTD: +25.9%
1Y: +13.5%
3Y: -69.1%
5Y: -78.6%
$15.10
-0.02 (-0.13%)
Weekly Expected Move ±14.7%
$10
$12
$14
$16
$18
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.60
Bullish
2 bullish
1 neutral
0 bearish
Articles (24h)
3
Hourly Sentiment (24h)
0.54
Bullish
3 bullish
2 neutral
0 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (62)
4 High-Growth GARP Stocks With Attractive PEG Ratios for 2026
Should You Continue to Hold Labcorp Stock in Your Portfolio?
Integra LifeSciences (IART) is a Top-Ranked Value Stock: Should You Buy?
IART or MASI: Which Is the Better Value Stock Right Now?
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
Integra (IART) Upgraded to Buy: What Does It Mean for the Stock?
Integra LifeSciences Holdings Corporation Q1 2026 Earnings Call Summary
Integra (IART) Q1 2026 Earnings Call Transcript
Integra outlines 2026 adjusted EPS of $2.40 to $2.50 while maintaining $1.66B to $1.70B revenue guidance
Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday
Integra Lifesciences Q1 2026 Earnings Call Transcript
Integra (IART) Reports Q1 Earnings: What Key Metrics Have to Say
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Earnings Scheduled For May 5, 2026
Integra LifeSciences names Stuart Essig as CEO
Integra LifeSciences Reports First Quarter 2026 Financial Results
Integra LifeSciences Announces Leadership Transition
Integra LifeSciences Reports First Quarter 2026 Financial Results
Here are the major earnings before the open Tuesday
Integra LifeSciences Holdings Corporation Q1 2026 Earnings Preview
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Is This the Right Time to Hold IART Stock in Your Portfolio?
AxoGen (AXGN) Q1 Earnings Lag Estimates
Analysts Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) PT at $14.20
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
INTEGRA SHAREHOLDER ALERT: Kaskela Law Firm Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (IART) and Encourages Long-Term Integra Investors to Contact the Firm
Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
Why Integra (IART) is Poised to Beat Earnings Estimates Again
Analysts Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Price Target at $14.40
Assenagon Asset Management S.A. Boosts Stock Holdings in Integra LifeSciences Holdings Corporation $IART
Global Intracranial Pressure Monitoring Devices Market Size/Share Worth USD 3.71 Billion by 2035 at a 7.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
Global Intracranial Pressure Monitoring Devices Market Size/Share Worth USD 3.71 Billion by 2035 at a 7.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Should You Continue to Hold Integra Stock in Your Portfolio Now?
Integra LifeSciences (NASDAQ:IART) Reaches New 12-Month Low Following Analyst Downgrade
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives $14.80 Average PT from Analysts
Integra LifeSciences (NASDAQ:IART) Trading Down 7.7% on Analyst Downgrade
Integra Q4 Earnings & Revenues Beat Estimates, Margins Down, Stock Up
Integra LifeSciences (NASDAQ:IART) Sets New 1-Year Low After Analyst Downgrade
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation Non-GAAP EPS of $0.83 beats by $0.03, revenue of $434.9M beats by $5.28M
Integra (IART) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
Brokerages Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Target Price at $15.00
Access Investment Management LLC Lowers Stake in Integra LifeSciences Holdings Corporation $IART
168,000 Shares in Integra LifeSciences Holdings Corporation $IART Purchased by Hussman Strategic Advisors Inc.
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives $15.00 Average PT from Brokerages
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
Integra LifeSciences Holdings Corporation $IART Shares Sold by Assenagon Asset Management S.A.
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
AXQ Capital LP Takes Position in Integra LifeSciences Holdings Corporation $IART